DJ MARKET TALK: Actelion CoTherix Deal Is Excellent -C Suisse

11/20/06 - Dow Jones Newswires

1309 GMT [Dow Jones]--Actelion's (ATLN.EB) CoTherix buy is an excellent strategic deal at a good price, says Credit Suisse. Leveraging the US commercialization rights to Ventavis is key, an analyst says. "Arguably, Actelion with its leading position in the PAH field should be able to leverage Ventavis to a greater extend than CoTherix." Actelion shares trade +6.1% at CHF214.40. (HJS)

 
Contact us in London. +44-20-7842-9464 
Markettalk.eu@dowjones.com 
 
 

(END) Dow Jones Newswires

November 20, 2006 08:09 ET (13:09 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc.